{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:29Z","timestamp":1787840429561,"version":"build-2784847793"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"\n A\n BSTRACT<\/jats:sc>\n <\/jats:title>\n \n Objective:<\/jats:title>\n This study sought to assess the prevalence of adverse events following immunization (AEFI) and factors associated with AEFI of the ChAdOx1 nCoV-19 vaccine (Covishield) among healthcare workers (HCW) of a medicine-teaching institution of North India.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n A cross-sectional study was conducted in the months of June and July 2021 among HCW (\n N<\/jats:italic>\n = 203) of 18 years and above, vaccinated with at least the first dose of Covishield. A semi-structured, prevalidated, and pretested questionnaire was used to collect information through an interview schedule. The questionnaire was divided into five sections: the sociodemographic profile, behavioral characteristics, past medical history, COVID-19 awareness, and past infection and COVID-19 vaccine related information. Chi-squared test was applied to check the association of different factors with AEFI.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n In our study, 73.89% of participants suffered from at least one AEFI after the first dose of the vaccine, while 48.66% had at least one AEFI after the second dose. Females reported significantly high AEFI for both doses (\n P<\/jats:italic>\n = 0.001, 0.000). We found a significant association between the occurrence of AEFI and occupation (first dose\n P<\/jats:italic>\n = 0.015), substance abuse (first dose\n P<\/jats:italic>\n = 0.002), diet (first dose\n P<\/jats:italic>\n = 0.016), and allergy (first dose\n P<\/jats:italic>\n = 0.027). Other significant findings were headaches among HCW \u226540 years of age (dose\n P<\/jats:italic>\n = 0.034) and systemic AEFI in participants with comorbidity (first dose\n P<\/jats:italic>\n = 0.020).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n More AEFI were reported after the first dose as compared to the second dose. AEFI were more among females after both the doses. Occupation, substance use, diet, and history of allergy were significantly associated with AEFI.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_1123_23","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T06:10:02Z","timestamp":1707372602000},"page":"298-310","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India"],"prefix":"10.4103","volume":"13","author":[{"given":"Abhinav","family":"Jha","sequence":"first","affiliation":[{"name":"Medical Student (MBBS Intern), Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Oto-Rhino-Laryngology, Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelesh K.","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Principal Autonomous State Government Medical College, Lakhimpur Kheri, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorv A.","family":"Bharatwal","sequence":"additional","affiliation":[{"name":"Medical Student (MBBS Intern), Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Dhamnetiya","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital, Connaught Place, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Singh","sequence":"additional","affiliation":[{"name":"Medical Student (MBBS Intern), Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi P.","family":"Jha","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"R8-20240828","doi-asserted-by":"crossref","DOI":"10.1016\/j.lansea.2022.100139","article-title":"Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2\/3, observer-blind, randomised, controlled study","volume":"10","author":"Kulkarni","year":"2023","journal-title":"The Lancet Regional Health-Southeast Asia"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3390\/diagnostics11060955","article-title":"COVID-19 vaccine and death: Causality algorithm according to the WHO eligibility diagnosis","volume":"11","author":"Pomara","year":"2021","journal-title":"Diagnostics"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"101218","DOI":"10.1016\/j.eclinm.2021.101218","article-title":"A phase 2\/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India","volume":"42","author":"Kulkarni","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R19-20240828","first-page":"e21809","article-title":"Adverse events following COVID-19 vaccination in selected apartments in Bangalore, India","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cureus"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ihj.2022.01.002","article-title":"Coronary thrombo-embolic events after Covid-19 vaccination-a single centre study","volume":"74","author":"Showkathali","year":"2022","journal-title":"Indian Heart J"},{"key":"R21-20240828","first-page":"e21848","article-title":"Incidence, pattern and severity of adverse events following immunization (AEFIs) associated with ChAdOx1 nCOV-19 corona virus vaccine (recombinant) among the healthcare workers of a tertiary care institute of eastern Uttar Pradesh, India","volume":"14","author":"Kamble","year":"2022","journal-title":"Cureus"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/1574886317666220113101815","article-title":"ADR profile of the covishield vaccine among healthcare workers in a tertiary care teaching hospital in India","volume":"17","author":"Deb","year":"2022","journal-title":"Curr Drug Saf"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1574886317666220207120649","article-title":"Active symptom-based surveillance of adverse events following immunization among individuals vaccinated with ChAdO\u00d71 nCoV-19 coronavirus vaccine in a tertiary hospital of Kerala","volume":"17","author":"Jose","year":"2022","journal-title":"Curr Drug Saf"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1016\/j.vaccine.2020.07.013","article-title":"Planning for COVID-19 vaccines safety surveillance","volume":"38","author":"Kochhar","year":"2020","journal-title":"Vaccine"},{"key":"R27-20240828","year":"2020"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s42399-021-01021-z","article-title":"Adverse events following COVISHIELD vaccination among adult population in Bangladesh","volume":"3","author":"Khalil","year":"2021","journal-title":"SN Compr Clin Med"},{"issue":"Suppl 2","key":"R29-20240828","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1016\/j.mjafi.2021.06.014","article-title":"Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study","volume":"77","author":"Kamal","year":"2021","journal-title":"Med J Armed Forces India"},{"key":"R30-20240828","first-page":"e339","article-title":"Covishield India: demystifying myths through an early multicenter study","volume":"27","author":"Mohakuda","year":"2021","journal-title":"Am J Manag Care"},{"key":"R31-20240828","doi-asserted-by":"crossref","first-page":"25151355211055833","DOI":"10.1177\/25151355211055833","article-title":"Adverse events following COVID-19 vaccination: First 90 days of experience from a tertiary care teaching hospital in South India","volume":"9","author":"Basavaraja","year":"2021","journal-title":"Ther Adv Vaccines Immunother"},{"key":"R32-20240828","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/vaccines9101096","article-title":"Adverse events following immunization associated with the first and second doses of the ChAdOx1 nCoV-19 vaccine among healthcare workers in Korea","volume":"9","author":"Jeon","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"R33-20240828","doi-asserted-by":"crossref","first-page":"101038","DOI":"10.1016\/j.eclinm.2021.101038","article-title":"A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India","volume":"38","author":"Kaur","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R34-20240828","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/idr13040080","article-title":"Side effects following administration of the first dose of Oxford-AstraZeneca's covishield vaccine in Bangladesh: A cross-sectional study","volume":"13","author":"Jahan","year":"2021","journal-title":"Infect Dis Rep"},{"key":"R35-20240828","doi-asserted-by":"crossref","first-page":"108136","DOI":"10.1016\/j.intimp.2021.108136","article-title":"Adverse events occurring post-covid-19 vaccination among healthcare professionals-A mixed method study","volume":"100","author":"Mahapatra","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R36-20240828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3126\/jpahs.v8i1.36242","article-title":"Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal","volume":"8","author":"Shrestha","year":"2021","journal-title":"J Patan Acad Heal Sci"},{"key":"R37-20240828","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13690-021-00741-x","article-title":"Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021","volume":"79","author":"Konu","year":"2021","journal-title":"Arch Public Health"},{"key":"R38-20240828","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1123_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:29Z","timestamp":1787836949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1123_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1123_23","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-07-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}